Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid

Background: The search for a biomarker of Alzheimer’s disease (AD) pathology (amyloid-β (Aβ) and tau) is ongoing, with the best markers currently being measurements of Aβ and tau in cerebrospinal fluid (CSF) and via positron emission tomography (PET) scanning. These methods are relatively invasive,...

Descripción completa

Detalles Bibliográficos
Autores principales: Voyle, Nicola, Patel, Hamel, Folarin, Amos, Newhouse, Stephen, Johnston, Caroline, Visser, Pieter Jelle, Dobson, Richard J.B., Kiddle, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181674/
https://www.ncbi.nlm.nih.gov/pubmed/27834776
http://dx.doi.org/10.3233/JAD-160707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181674/
https://www.ncbi.nlm.nih.gov/pubmed/27834776
http://dx.doi.org/10.3233/JAD-160707

Ejemplares similares